

# Regulatory Perspective on Safety Qualification of Extractables and Leachables

**Ingrid Markovic, Ph.D.**  
Expert Review Scientist

U.S. Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Biotechnology Products  
Division of Therapeutic Proteins

*PQRI Workshop on Thresholds and Best Practices for Parenteral and Ophthalmic  
Drug Products (PODP)*

# Risk-based Approach in Evaluating E&L

- **Safety considerations** (e.g., toxicity, immunogenicity, etc.)
- **Efficacy considerations** (e.g., L interacting with a product → loss of activity; L may induce development of neutralizing activity via NAb formation)
- **Quality considerations** (e.g., impact on the manufacturing process, product stability, etc.)



U.S. Food and Drug Administration  
Protecting and Promoting Public Health

## Safety considerations

- Toxicity (e.g., acute, chronic, synergistic, additive, carcinogenic, endocrine dysregulation, etc.)
- Adjuvant effects:
  - Adjuvants are substances that increase the activity of the immune system without having any specific antigenic effect
  - In contrast to vaccines where adjuvant effect is a desired effect, there may be a serious safety concern for therapeutic proteins
  - May promote development of anti-drug antibodies
    - ❖ A decrease or loss of efficacy due to development of neutralizing antibodies
    - ❖ May be life-threatening if NABs are developed against a non-redundant endogenous protein (e.g., erythropoietin - anemia/PRCA; thrombopoietin - thrombocytopenia)
    - ❖ Altering the PK of the drug
  - May promote non-specific inflammation

## **Safety considerations (cont.)**

- **Drug dose, mode and frequency of administration (e.g., SC vs. IV, life-time dosing and chronic exposure)**
- **Prior clinical exposure to leachables may enhance sensitivity in case of re-exposure**
- **Therapeutic necessity of the drug (higher levels may be tolerated if drug is considered a part of essential therapy)**



U.S. Food and Drug Administration  
Protecting and Promoting Public Health

# Manufacturing considerations

- Place in the process stream (e.g., upstream vs. downstream; typically risks are greater as production moves closer to the finished product)
- Type of the processed/stored material (e.g., purification buffer final product)
- Storage temperature (e.g., freezing vs. 2-8 C)
- Surface-to-volume ratio
- Contact time
- Type of polymeric material (e.g., PVC at risk for leaching di(2-ethylhexyl)phthalate, which is linked to various toxicities)
- Formulation/choice of excipients; (e.g., liquid vs. lyophilized; phosphate buffer)

• Disks often accessed on a case-by-case basis

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.